July 26, 2019

Mylan issued an alert in June on the manufacturing challenges about the production of EpiPen (epinephrine injection, USP) 0.3 mg and EpiPen Jr (epinephrine Injection, USP) 0.15 mg Auto-Injectors, and the authorized generic versions of these strengths. These challenges resulted in the reduced availability of these products. Effective July 26, VDP will temporarily remove the non-preferred status from the following epinephrine NDCs for people enrolled in Medicaid:

NDC Name
00115169449 Epinephrine 0.3 mg auto-injector
00115169549 Epinephrine 0.15 mg Auto -Injector

This change allows providers to prescribe for these two product NDCs without requiring a PDL prior authorization. This change also allows continued access to necessary medication for Medicaid clients. The current preferred products are:

NDC Name
49502010101 Epinephrine 0.15 mg auto-injector
49502010102 Epinephrine 0.15 mg auto-injector
49502010201 Epinephrine 0.3 mg auto-injector
49502010202 Epinephrine 0.3 mg auto-injector

This change is temporary until the preferred products are sufficiently available in the market. VDP will provide announcements regarding future PDL status changes of these NDCs.